214 related articles for article (PubMed ID: 36580661)
21. Structural rearrangements at physiological pH: nuclear magnetic resonance insights from the V210I human prion protein mutant.
Biljan I; Ilc G; Giachin G; Plavec J; Legname G
Biochemistry; 2012 Sep; 51(38):7465-74. PubMed ID: 22947063
[TBL] [Abstract][Full Text] [Related]
22. The roles of the conserved tyrosine in the β2-α2 loop of the prion protein.
Huang D; Caflisch A
Prion; 2015; 9(6):412-9. PubMed ID: 26689486
[TBL] [Abstract][Full Text] [Related]
23. Thermodynamic stabilization of the folded domain of prion protein inhibits prion infection in vivo.
Kong Q; Mills JL; Kundu B; Li X; Qing L; Surewicz K; Cali I; Huang S; Zheng M; Swietnicki W; Sönnichsen FD; Gambetti P; Surewicz WK
Cell Rep; 2013 Jul; 4(2):248-54. PubMed ID: 23871665
[TBL] [Abstract][Full Text] [Related]
24. The role of Cys179-Cys214 disulfide bond in the stability and folding of prion protein: insights from molecular dynamics simulations.
Ning L; Guo J; Jin N; Liu H; Yao X
J Mol Model; 2014 Feb; 20(2):2106. PubMed ID: 24515720
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics studies on the buffalo prion protein.
Zhang J; Wang F; Chatterjee S
J Biomol Struct Dyn; 2016; 34(4):762-77. PubMed ID: 26043781
[TBL] [Abstract][Full Text] [Related]
26. Disassociation of β1-α1-β2 from the α2-α3 domain of prion protein (PrP) is a prerequisite for the conformational conversion of PrP
Chandrasekaran P; Santosh Kumar C; Rangachari K; Sekar K
Int J Biol Macromol; 2019 Sep; 136():368-376. PubMed ID: 31207327
[TBL] [Abstract][Full Text] [Related]
27. Pathogenic mutations in the hydrophobic core of the human prion protein can promote structural instability and misfolding.
van der Kamp MW; Daggett V
J Mol Biol; 2010 Dec; 404(4):732-48. PubMed ID: 20932979
[TBL] [Abstract][Full Text] [Related]
28. Systematic investigation of predicted effect of nonsynonymous SNPs in human prion protein gene: a molecular modeling and molecular dynamics study.
Jahandideh S; Zhi D
J Biomol Struct Dyn; 2014; 32(2):289-300. PubMed ID: 23527686
[TBL] [Abstract][Full Text] [Related]
29. Human prion protein: exploring the thermodynamic stability and structural dynamics of its pathogenic mutants.
Halder P; Mitra P
J Biomol Struct Dyn; 2022; 40(21):11274-11290. PubMed ID: 34338141
[TBL] [Abstract][Full Text] [Related]
30. Insights into structural properties of denatured human prion 121-230 at melting temperature studied by replica exchange molecular dynamics.
Tang JL; Wu PJ; Wang SC; Lee CI
J Phys Chem B; 2012 Mar; 116(10):3305-12. PubMed ID: 22339436
[TBL] [Abstract][Full Text] [Related]
31.
Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
[TBL] [Abstract][Full Text] [Related]
32. Protein misfolding cyclic amplification (PMCA): Current status and future directions.
Saá P; Cervenakova L
Virus Res; 2015 Sep; 207():47-61. PubMed ID: 25445341
[TBL] [Abstract][Full Text] [Related]
33. The Prion Concept and Synthetic Prions.
Legname G; Moda F
Prog Mol Biol Transl Sci; 2017; 150():147-156. PubMed ID: 28838659
[TBL] [Abstract][Full Text] [Related]
34. Horse prion protein NMR structure and comparisons with related variants of the mouse prion protein.
Pérez DR; Damberger FF; Wüthrich K
J Mol Biol; 2010 Jul; 400(2):121-8. PubMed ID: 20460128
[TBL] [Abstract][Full Text] [Related]
35. Structural basis for the complete resistance of the human prion protein mutant G127V to prion disease.
Zheng Z; Zhang M; Wang Y; Ma R; Guo C; Feng L; Wu J; Yao H; Lin D
Sci Rep; 2018 Sep; 8(1):13211. PubMed ID: 30181558
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological chaperone for the structured domain of human prion protein.
Nicoll AJ; Trevitt CR; Tattum MH; Risse E; Quarterman E; Ibarra AA; Wright C; Jackson GS; Sessions RB; Farrow M; Waltho JP; Clarke AR; Collinge J
Proc Natl Acad Sci U S A; 2010 Oct; 107(41):17610-5. PubMed ID: 20876144
[TBL] [Abstract][Full Text] [Related]
37. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
[TBL] [Abstract][Full Text] [Related]
38. Experiment and molecular dynamics simulations reveal proanthocyanidin B2 and B3 can inhibit prion aggregation by different mechanisms.
Li Q; Zhu Y; Meng X; Tong HHY; Liu H
J Biomol Struct Dyn; 2024 Mar; 42(5):2424-2436. PubMed ID: 37144732
[TBL] [Abstract][Full Text] [Related]
39. Distinct effects of mutations on biophysical properties of human prion protein monomers and oligomers.
Yu Y; Yu Z; Zheng Z; Wang H; Wu X; Guo C; Lin D
Acta Biochim Biophys Sin (Shanghai); 2016 Nov; 48(11):1016-1025. PubMed ID: 27649893
[TBL] [Abstract][Full Text] [Related]
40. Peroxymonosulfate Rapidly Inactivates the Disease-Associated Prion Protein.
Chesney AR; Booth CJ; Lietz CB; Li L; Pedersen JA
Environ Sci Technol; 2016 Jul; 50(13):7095-105. PubMed ID: 27247993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
